OnKure Therapeutics (OKUR)
NASDAQ:OKUR
Want to see OKUR full AI Analyst Report?
OKUR Stock Chart & Stats
$4.51
-$0.05(-0.63%)
At close: 4:00 PM EST
$4.51
-$0.05(-0.63%)
Day’s Range― - ―
52-Week Range$1.70 - $4.75
Previous CloseN/A
Volume8.61K
Average Volume (3M)86.56K
Market Cap
$61.67M
Enterprise Value$5.35M
Total Cash (Recent Filing)$59.05M
Total Debt (Recent Filing)$549.00K
Price to Earnings (P/E)―
Beta1.12
Next Earnings
May 12, 2026EPS Estimate
-0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.99
Shares Outstanding13,673,565
10 Day Avg. Volume131,167
30 Day Avg. Volume86,556
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.70
Price to Sales (P/S)0.00
P/FCF Ratio-0.76
Enterprise Value/Market Cap0.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-26.51
Enterprise Value/Ebitda-0.09
Forecast
1Y Price Target
$22.50Price Target Upside398.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-3.15
Revenue Forecast (FY)$666.67K
Bulls Say, Bears Say
Bulls Say
Capital SupportAnalyst highlights a concurrent private financing that will provide additional capital to support continued development of the pipeline and reduce near-term funding pressure.
Clinical Progress And PositioningAnalyst highlights initiation and dosing of triplet therapy arms combining OKI-219 with established endocrine and HER2-targeted agents as evidence of active clinical progress that could support positioning in earlier-line treatment.
Pipeline DiversificationAnalyst notes that two new drug candidates targeting multiple common mutations expand the company's development pipeline into both cancer and vascular malformation indications, potentially opening new market opportunities.
Bears Say
Cash Runway And Financing RiskAnalyst notes high annual cash burn and modest available cash relative to projected needs, increasing the likelihood that additional financing will be required to sustain development activities.
Incomplete Mature Efficacy EndpointsAnalyst cautions that durable outcome measures such as progression-free survival may not be available for every treatment arm, which could limit the ability to draw definitive conclusions from clinical updates.
Uncertain Potency Across MutationsAnalyst warns the actual potency of the new candidates across the full spectrum of target mutations remains to be determined, creating uncertainty about likely clinical effectiveness.
OnKure Therapeutics News
OKUR FAQ
What was OnKure Therapeutics’s price range in the past 12 months?
OnKure Therapeutics lowest stock price was $1.70 and its highest was $4.75 in the past 12 months.
What is OnKure Therapeutics’s market cap?
OnKure Therapeutics’s market cap is $61.67M.
When is OnKure Therapeutics’s upcoming earnings report date?
OnKure Therapeutics’s upcoming earnings report date is May 12, 2026 which is in 25 days.
How were OnKure Therapeutics’s earnings last quarter?
OnKure Therapeutics released its earnings results on Mar 12, 2026. The company reported -$0.99 earnings per share for the quarter, beating the consensus estimate of -$1.152 by $0.162.
Is OnKure Therapeutics overvalued?
According to Wall Street analysts OnKure Therapeutics’s price is currently Undervalued.
Does OnKure Therapeutics pay dividends?
OnKure Therapeutics does not currently pay dividends.
What is OnKure Therapeutics’s EPS estimate?
OnKure Therapeutics’s EPS estimate is -0.74.
How many shares outstanding does OnKure Therapeutics have?
OnKure Therapeutics has 13,673,565 shares outstanding.
What happened to OnKure Therapeutics’s price movement after its last earnings report?
OnKure Therapeutics reported an EPS of -$0.99 in its last earnings report, beating expectations of -$1.152. Following the earnings report the stock price went up 7.386%.
Which hedge fund is a major shareholder of OnKure Therapeutics?
Currently, no hedge funds are holding shares in OKUR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OnKure Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.50 (398.89% Upside)
$22.50 (398.89% Upside)
Hedge Fund Trend
Decreased
By 107.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 39.0%
Last 30 Days ▲ 39.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-84.51%
12-Months-Change
Fundamentals
Return on Equity
-115.64%
Trailing 12-Months
Asset Growth
9.34%
Trailing 12-Months
Company Description
OnKure Therapeutics
OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.
OKUR Stock 12 Month Forecast
Average Price Target
$22.50
▲(398.89% Upside)